Megan Flott, PA
Medical · Mooresville, NCNPI 1194051508
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 904 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 904 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Neurocrine Biosciences, Inc.$953
- Sunovion Pharmaceuticals Inc.$880
- plus $6K from 24 others
What the payments were for
- Food & beverage$14,304100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 134 | $1,863 |
| Otsuka America Pharmaceutical, Inc. | 83 | $1,720 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 65 | $1,311 |
| AbbVie | 104 | $1,118 |
| Neurocrine Biosciences, Inc. | 49 | $953 |
| Sunovion Pharmaceuticals Inc. | 96 | $880 |
| Lundbeck LLC | 48 | $800 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $668 |
| Axsome Therapeutics, Inc. | 42 | $654 |
| Almatica Pharma LLC | 38 | $545 |
| Johnson & Johnson | 24 | $543 |
| Supernus Pharmaceuticals, Inc. | 26 | $488 |
| Neos Therapeutics, LP | 31 | $469 |
| Merck | 15 | $297 |
| Alkermes, Inc. | 13 | $292 |
| Vanda Pharmaceuticals Inc. | 16 | $282 |
| Idorsia Pharmaceuticals US Inc | 12 | $247 |
| E.r. Squibb & Sons, L.L.C. | 16 | $242 |
| Tris Pharma Inc | 13 | $227 |
| Noven Therapeutics, LLC | 10 | $174 |
| Corium, LLC | 9 | $150 |
| Eisai Inc. | 6 | $93 |
| Indivior Inc. | 4 | $76 |
| Acadia Pharmaceuticals Inc | 2 | $51 |
| Livanova USA, Inc. | 2 | $44 |
| Harmony Biosciences LLC | 1 | $31 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $28 |
| Adlon Therapeutics L.p. | 2 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $17 |
How this compares
$14,307 in reported general payments places this provider in the 95th percentile of 878 medical providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 17 | $358,869 |
| VraylarCariprazine Hcl | 31 | $49,451 |
| TrintellixVortioxetine Hydrobromide | 20 | $16,646 |
| Lurasidone Hcl | 21 | $15,005 |
| BelsomraSuvorexant | 14 | $6,013 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 61 | $2,038 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $1,821 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 53 | $1,465 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 16 | $1,398 |
| Duloxetine Hcl | 71 | $1,320 |
| Bupropion XlBupropion Hcl | 48 | $1,219 |
| Aripiprazole | 34 | $1,173 |
| Clonazepam | 78 | $1,169 |
| Lamotrigine | 45 | $816 |
| Escitalopram Oxalate | 50 | $803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,863 | $358,86917 claims |
| AbbVieVraylar | $1,118 | $49,45131 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $668 | $16,64620 claims |
| MerckBelsomra | $297 | $6,01314 claims |
| Almatica Pharma LLCSertraline Hcl | $545 | $38345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 medical providers in North Carolina.
Other medical in Mooresville
- Kimberly MessinaMooresville$9K
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$265K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- Amanda ZimmermanWinston Salem$48K
- David TaylorMorehead City$40K
- Katherine CardSalisbury$39K
- John RobbinsWinston Salem$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.